Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03236116 · ClinicalTrials.gov registry record · NA

Almond Consumption and Glycemia

A NA study of Glucose Intolerance and Glucose Metabolism Disorders (Including Diabetes Mellitus), sponsored by Purdue University.

Completed
Registry status
NA
Development phase
75
Enrollment target
3
Study locations

NCT03236116 is a NA study of Glucose Intolerance and Glucose Metabolism Disorders (Including Diabetes Mellitus) that has completed, run by Purdue University. The registered enrollment target is 75 participants, below the 3,854-participant average among 14 other Glucose Intolerance trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03236116, a NA study of Glucose Intolerance and Glucose Metabolism Disorders (Including Diabetes Mellitus), has completed, sponsored by Purdue University.

COMPLETED
Registry status
NA
Development phase
75 participants
Enrollment target
3
Study locations

Study Summary

This study will examine the effects of almonds consumed by adults with different body fat distributions on indices of carbohydrate and lipid metabolism.

Interventions

  • OTHER Almonds
  • OTHER Control (no nuts)

Study Locations (3)

Indiana

  • Indiana University School of Medicine - Indianapolis
  • Purdue University - West Lafayette
  • Purdue University - West Lafayette

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2017-08-01
Est. Completion 2020-12-31
Phase NA

Sponsor

Purdue University

141 total trials

What the Registry Record Tells You About NCT03236116

The ClinicalTrials.gov registry entry for NCT03236116 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,854-participant average among 14 other Glucose Intolerance trials with a reported enrollment target (98% lower). The listed sponsor is Purdue University, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Glucose Intolerance appearing as the primary indexed condition, and to 2 interventions - of which Almonds is the first listed.

NCT03236116 reports 3 study locations spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT03236116 about?

NCT03236116 is a clinical study titled "Almond Consumption and Glycemia". This study will examine the effects of almonds consumed by adults with different body fat distributions on indices of carbohydrate and lipid metabolism.

What is the current status of trial NCT03236116?

This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2017-08-01. Estimated completion is 2020-12-31.

What conditions does trial NCT03236116 study?

This clinical trial studies the following conditions: Glucose Intolerance, Glucose Metabolism Disorders (Including Diabetes Mellitus), Lipid Metabolism Disorder, Appetite Disorders.

What interventions are being tested in trial NCT03236116?

The interventions under investigation include: Almonds (OTHER), Control (no nuts) (OTHER).

Who is sponsoring clinical trial NCT03236116?

This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03236116 being conducted?

This trial has 3 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glucose Intolerance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.